...A. Wehmeier; R.E. Scharf; S. Fricke; W. Schneider Bleeding and thrombosis are a major cause of morbidity and mortality in myeloproliferative disorders (MPD). This study evaluates the relation between thrombohemorrhagic complications and platelet abnormalities in different subgroups of MPD. In 57...

... extract was studied in 14 patients with myeloproliferative disorders (MPD) and 7 normal subjects. Reduced mitogenic activity was found in PRS and platelet extract of patients with MPD, as compared to controls. The average levels of platelet-derived growth factor (PDGF) equivalents were as follows: 16.3...

...Piera Viero; Sergio Cortelazzo; Tiziano Barbui; Giovanni de Gaetano Platelets from 6 out of 10 patients with myeloproliferative disorders showed only a single reversible wave of aggregation when challenged with platelet activating factor (PAF). Preexposure to subthreshold concentrations...

...Judit H. Breuer; Veronika Harsányi; Veronika Solti; Susan R. Hollán Platelet phospholipids were analyzed in patients with thrombocytosis due to myeloproliferative disorders and secondary thrombocytosis. A significant increase of phos-phatidylcholine together with a decrease of sphingomyelin...

... system activation in patients with Bcl-negative myeloproliferative disorders. 27 1 2009 © 2009 S. Karger AG, Basel 2007 Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any...